

August 12, 2026

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

PR Release

**SHED Clinical Study for Cerebral Palsy
Data Safety Monitoring Board Confirms “No Safety Concerns”
Across All Patients and Throughout the Full Observation Period**

Tokyo, August 12, 2026 - Kidswell Bio Group is engaged in the research and development of novel cell-based therapies (regenerative medicine products) utilizing stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

In the clinical trial entitled “A clinical trial to evaluate the safety and tolerability of stem cells from human exfoliated deciduous teeth in children with cerebral palsy”, led by Nagoya University and jointly conducted with our subsidiary, S-Quatre Corporation, the Data Safety Monitoring Board (DSMB)—an independent body distinct from the research institution—convened to review safety outcomes in accordance with the study protocol.

In October 2025, the DSMB reviewed safety data from this clinical study through four weeks post-administration and concluded that there were no safety concerns. The DSMB subsequently conducted a further assessment to confirm safety following completion of the full observation period. Based on its review of all three patients through 52 weeks post-administration, the DSMB concluded that “no adverse events attributable to the intravenous administration of autologous stem cells from human exfoliated deciduous tooth were observed, and no safety concerns were identified through 52 weeks post-administration.”

This favorable outcome marks the successful completion of the safety evaluation in this clinical study and represents an important milestone supporting the planned clinical trial of allogeneic SQ-SHED.

The final analysis of efficacy is also currently underway, with the results expected to be announced by Nagoya University by the end of 2026. Our group will continue advancing research and development to establish innovative therapies for cerebral palsy and other intractable diseases.

■Related release

[Administration Completed in All Three Patients in Clinical Study Using SHED for the Treatment of Pediatric Cerebral Palsy](#), June 24, 2025

[SHED Clinical Study for Cerebral Palsy Data Safety Monitoring Board Confirms “No Safety Concerns”](#), October 7, 2025

[Interim Results of SHED Clinical Study for Children with Cerebral Palsy Disclosed by Nagoya University](#), November 17, 2025

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.